Assessment of copeptin, ghrelin and pro BNP in metabolic syndrome

Abstract

This study was aimed to assessment the relationship between MetS and three different biomarkers (Copeptin, Ghrelin and NT-proBNP) that related to metabolism and cardiovascular system. Metabolic syndrome (MetS) is a multifactorial disorder with metabolic abnormalities including central obesity, insulin resistance, atherogenic dyslipidemia, and hypertension that increase the risk of the development of diabetes and cardiovascular disease (CVD) at highly rates. Methods: Our study was evaluated according to the metabolic syndrome diagnostic criteria of the American Heart Association/National Heart, Lung and Blood Institute (AHA/NHL-BI) and the International Diabetes Federation (IDF). A total of seventy four subjects (44-MetS and 30-healthy) included in this study. Copeptin and ghrelin were determined using the ELISA. The amino-terminal pro-brain natriuretic peptide (NT-proBNP) was measured through chemiluminescence method. The biochemical parameters including blood glucose-insulin values, lipid profiles were also measured. Results: Total cholesterol, fasting blood glucose, insulin, LDL were significantly higher in the MetS than healthy and HDL was significantly lower. There was no significant difference between thyroid tests. Copeptin was significantly higher in MetS than healthy (p=0.007). Ghrelin was lower in MetS than in the healthy (p=0.002). ProBNP was higher in Mets compared to the control (p=0.028). Conclusion: Copeptin, Ghrelin and ProBNP are directly related not only in itself but also to various metabolic syndrome components. With the data obtained in our study, it is thought to be a guide in follow-up of high risk patients.